Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. - Kater AP; Kersting S; Dubois JM; van der Holt B; da Cunha-Bang C; Te Raa D; Idink C; de Boer F; Droogendijk J; de Heer K; van der Burg L; Nijziel MR; et al. (The Lancet. Haematology, 2025)